Livalo FDA Approval History
FDA Approved: Yes (First approved August 3, 2009)
Brand name: Livalo
Generic name: pitavastatin
Dosage form: Tablets
Company: Kowa Company, Ltd.
Treatment for: High Cholesterol
Livalo (pitavastatin) is an HMG CoA reductase inhibitor indicated for the primary treatment of hypercholesterolemia and combined dyslipidemia.
Development timeline for Livalo
| Date | Article |
|---|---|
| Aug 4, 2009 | Approval FDA Approves Livalo for Primary Hypercholesterolemia and Combined Dyslipidemia |
| Oct 28, 2008 | Kowa Announces NDA Submission and MAA Filing for HMG CoA Reductase Inhibitor Pitavastatin |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.